1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333 – 40.
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179 – 86.
3. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 2007; 119:852 – 60.
4. Bocchini JA Jr, Bradley JS, Brady MT, et al.; American Academy of Pediatrics Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children,2008–2009. Pediatrics 2008; 122:1135 – 41.
5. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influ- enza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):1 – 60.
6. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ 1979; 121:1193 – 254.
7. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. 15 August 2007. Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/clinical manage07/en/index.html. Accessed 4 March 2009.
8. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261 – 73.
9. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275 – 82.
10. Palese P, Shaw M. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. 5th ed. Vol. 2. Lip- pincott Williams & Wilkins, 2007:1647 – 90.
11. Matsuzaki Y, Katsushima N, Nagai Y, et al. Clinical features of influ- enza C virus infection in children. J Infect Dis 2006; 193:1229 – 35.
12. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treat- ment for healthy working adults. Ann Intern Med 2002; 137:225 – 31.
13. Sullivan KM, Monto AS, Longini IM Jr. Estimates of the US health impact of influenza. Am J Public Health 1993; 83:1712 – 6.
14. Evans CT, Lavela SL, Smith B, Miskevics S, Weaver FM, Goldstein B. Influenza diagnosis and treatment in veterans with spinal cord injury. Arch Phys Med Rehabil 2006; 87:291 – 3.
15. Linder JA, Bates DW, Platt R. Antivirals and antibiotics for influenza in the United States, 1995–2002. Pharmacoepidemiol Drug Saf 2005; 14:531 – 6.
16. Rothberg MB, Bonner AB, Rajab MH, Kim HS, Stechenberg BW, Rose DN. Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza. Clin Infect Dis 2006; 42:95 – 9.
17. Abanses JC, Dowd MD, Simon SD, Sharma V. Impact of rapid in- fluenza testing at triage on management of febrile infants and young children. Pediatr Emerg Care 2006; 22:145 – 9.
18. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. Am J Manag Care 2002; 8:221 – 7.
19. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Im- pact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: re- sults of a randomized, prospective, controlled trial. Pediatrics 2003;112:363 – 7.
20. D’Heilly SJ, Janoff EN, Nichol P, Nichol KL. Rapid diagnosis of in- fluenza infection in older adults: influence on clinical care in a routine clinical setting. J Clin Virol 2008; 42:124 – 8.
21. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on man- agement of adults hospitalized with influenza. Arch Intern Med 2007; 167:354 – 60.
22. Poehling KA, Zhu Y, Tang YW, Edwards K. Accuracy and impact of a point-of-care rapid influenza test in young children with respiratory illnesses. Arch Pediatr Adolesc Med 2006; 160:713 – 8.
23. Sharma V, Dowd MD, Slaughter AJ, Simon SD. Effect of rapid di- agnosis of influenza virus type A on the emergency department man- agement of febrile infants and toddlers. Arch Pediatr Adolesc Med 2002; 156:41 – 3.
24. Halloran ME, Piedra PA, Longini IM Jr, et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003 – 2004. Vaccine 2007; 25:4038 – 45.
25. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003 – 2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007; 120:e553 – 64.
26. Whitaker-Dowling P, Maassab HF, Youngner JS. Dominant-negative mutants as antiviral agents: simultaneous infection with the cold- adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A. J Infect Dis 1991; 164:1200 – 2.
27. Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000; 31:1166 – 9.
28. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? JAMA 2005; 293:987 – 97.
29. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243 – 7.
30. Quach C, Piche-Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics 2003; 112:e197 – 201.
31. Rojo JC, Ruiz-Contreras J, Fernandez MB, Marin MA, Folgueira L. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J 2006; 25:596 – 601.
32. Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36:111 – 6.
33. Wootton SH, Scheifele DW, Mak A, Petric M, Skowronski DM. De- tection of human influenza virus in the stool of children. Pediatr Infect Dis J 2006; 25:1194 – 5.
34. Meury S, Zeller S, Heininger U. Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr 2004; 163:359 – 63.
35. Guarner J, Paddock CD, Shieh WJ, et al. Histopathologic and im- munohistochemical features of fatal influenza virus infection in chil- dren during the 2003 – 2004 season. Clin Infect Dis 2006; 43:132 – 40.
36. Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations as- sociated with influenza virus infection. Int J Cardiol 2008; 130:304 – 9.
37. Abe M, Higuchi T, Okada K, Kaizu K, Matsumoto K. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol 2006; 66:166 – 70.
38. Annerstedt M, Herlitz H, Molne J, Oldfors A, Westberg G. Rhab- domyolysis and acute renal failure associated with influenza virus type A. Scand J Urol Nephrol 1999; 33:260 – 4.
39. Naderi AS, Palmer BF. Rhabdomyolysis and acute renal failure as- sociated with influenza virus type B infection. Am J Med Sci 2006; 332:88 – 9.
40. Maricich SM, Neul JL, Lotze TE, et al. Neurologic complications associated with influenza A in children during the 2003 – 2004 influ- enza season in Houston, Texas. Pediatrics 2004; 114:e626 – 33.
41. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encepha- lopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35:512 – 7.
42. Nagao T, Morishima T, Kimura H, et al. Prognostic factors in influ- enza-associated encephalopathy. Pediatr Infect Dis J 2008; 27:384 – 9.
43. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic com- plications in children hospitalized with influenza: characteristics, in- cidence, and risk factors. J Pediatr 2007; 150:306 – 10.
44. Steininger C, Popow-Kraupp T, Laferl H, et al. Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis 2003; 36:567 – 74.
45. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003 – 2004. N Engl J Med 2005; 353:2559 – 67.
46. Chang LY, Lee PI, Lin YJ, Chiu HH, Huang LM, Lee CY. Influenza B virus infection associated with shock in a two-month-old infant. J Formos Med Assoc 1996; 95:703 – 5.
47. Conway EE Jr, Haber RS, Gumprecht J, Singer LP. Toxic shock syn- drome following influenza A in a child. Crit Care Med 1991; 19:123 – 5.
48. MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influen- zalike illness. JAMA 1987; 257:1053 – 8.
49. Sharkey R, Mulloy E, O’Neill G, Walker F, O’Neill S. Toxic shock syndrome following influenza A infection. Intensive Care Med 1999; 25:335 – 6.
50. Tolan RW Jr. Toxic shock syndrome complicating influenza A in a child: case report and review. Clin Infect Dis 1993; 17:43 – 5.
51. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006; 6:303 – 12.
52. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003 – 04 influenza season. Emerg Infect Dis 2006;12:894 – 9.
53. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004; 23(Suppl1):S87 – 97.
54. Centers for Disease Control and Prevention. Severe methicillin-re- sistant Staphylococcus aureus community-acquired pneumonia asso- ciated with influenza—Louisiana and Georgia, December 2006 – Jan- uary 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325 – 9.
55. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mor- tality in the United States: increase of Staphylococcus aureus coinfec- tion. Pediatrics 2008; 122:805 – 11.
56. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as sec- ondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol 2006; 48:1498 – 502.
57. Mamas MA, Nair S, Fraser D. Cardiac tamponade and heart failure as a presentation of influenza. Exp Clin Cardiol 2007; 12:214 – 6.
58. Miller EK, Griffin MR, Edwards KM, et al. Influenza burden for children with asthma. Pediatrics 2008; 121:1 – 8.
59. Varkey JB, Varkey B. Viral infections in patients with chronic ob- structive pulmonary disease. Curr Opin Pulm Med 2008; 14:89 – 94.
60. Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like ill- ness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2006; 27:266 – 70.
61. Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998; 15:16 – 22.
62. Monmany J, Rabella N, Margall N, Domingo P, Gich I, Vazquez G. Unmasking influenza virus infection in patients attended to in the emergency department. Infection 2004; 32:89 – 97.
63. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997; 315:1060 – 4.
64. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002; 50:1498 – 503.
65. Carrat F, Leruez-Ville M, Tonnellier M, et al. A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Med 2006; 32:156 – 9.
66. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342:232 – 9.
67. Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuro- muscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA 2005; 294:2188 – 94.
68. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003 – 2005: implications for immunization recommen- dations. Pediatrics 2006; 117:e610 – 8.
69. Mullooly JP, Bridges CB, Thompson WW, et al. Influenza- and RSV- associated hospitalizations among adults. Vaccine 2007; 25:846 – 55.
70. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225 – 31.
71. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281:901 – 7.
72. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148:1094 – 102.
73. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000; 137:856 – 64.
74. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic in- fluenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002; 185:147 – 52.
75. O’Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004; 113:585 – 93.
76. Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in chil- dren: 2003 – 2004. Pediatr Infect Dis J 2006; 25:395 – 400.
77. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006; 194(Suppl 2):S111 – 8.
78. Horcajada JP, Pumarola T, Martinez JA, et al. A nosocomial outbreak of influenza during a period without influenza epidemic activity. Eur Respir J 2003; 21:303 – 7.
79. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sam- pathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28:1071 – 6.
80. Sagrera X, Ginovart G, Raspall F, et al. Outbreaks of influenza A virus infection in neonatal intensive care units. Pediatr Infect Dis J 2002;21:196 – 200.
81. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002; 2:145 – 55.
82. Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002; 23:615 – 9.
83. Slinger R, Dennis P. Nosocomial influenza at a Canadian pediatric hospital from 1995 to 1999: opportunities for prevention. Infect Con- trol Hosp Epidemiol 2002; 23:627 – 9.
84. Camps M, Vilella A, Marcos MA, et al. Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and subtropical areas. J Med Virol 2008; 80:711 – 5.
85. Luna LK, Panning M, Grywna K, Pfefferle S, Drosten C. Spectrum of viruses and atypical bacteria in intercontinental air travelers with symptoms of acute respiratory infection. J Infect Dis 2007; 195:675 – 9.
86. Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk pas- sengers and the global spread of new influenza viruses. Clin Infect Dis 2000; 31:433 – 8.
87. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005;40:1282 – 7.
88. Ortiz JR, Wallis TR, Katz MA, et al. No evidence of avian influenza A (H5N1) among returning US travelers. Emerg Infect Dis 2007; 13:294 – 7.
89. Uyeki TM, Zane SB, Bodnar UR, et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003; 36:1095-102.
90. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981; 144:433 – 41.
91. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24:931 – 2.
92. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reac- tion – restriction analysis. J Infect Dis 1995; 172:1352 – 5.
93. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised pa- tient. N Engl J Med 2003; 348:867 – 8.
94. Hota S, McGeer A. Antivirals and the control of influenza outbreaks. Clin Infect Dis 2007; 45:1362 – 8.
95. Frayha H, Castriciano S, Mahony J, Chernesky M. Nasopharyngeal swabs and nasopharyngeal aspirates equally effective for the diagnosis of viral respiratory disease in hospitalized children. J Clin Microbiol 1989; 27:1387 – 9.
96. Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses. J Clin Microbiol 2002; 40:4337 – 9.
97. Lambert SB, Whiley DM, O’Neill NT, et al. Comparing nose-throat swabs and nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real-time poly- merase chain reaction. Pediatrics 2008; 122:e615 – 20.
98. Sung RY, Chan PK, Choi KC, et al. Comparative study of nasopha- ryngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol 2008; 46:3073 – 6.
99. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influ- enza. Pediatr Infect Dis J 2003; 22:164 – 77.
100. Robinson JL, Lee BE, Kothapalli S, Craig WR, Fox JD. Use of throat swab or saliva specimens for detection of respiratory viruses in chil- dren. Clin Infect Dis 2008; 46:e61 – 4.
101. Simpson JL, Moric I, Wark PA, Johnston SL, Gibson PG. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques. J Clin Virol 2003; 26:339 – 46.
102. Kimball AM, Foy HM, Cooney MK, Allan ID, Matlock M, Plorde JJ. Isolation of respiratory syncytial and influenza viruses from the spu- tum of patients hospitalized with pneumonia. J Infect Dis 1983; 147:181 – 4.
103. Agoritsas K, Mack K, Bonsu BK, Goodman D, Salamon D, Marcon MJ. Evaluation of the Quidel QuickVue test for detection of influenza A and B viruses in the pediatric emergency medicine setting by use of three specimen collection methods. J Clin Microbiol 2006; 44:2638 – 41.
104. Dale SE, Mayer C, Mayer MC, Menegus MA. Analytical and clinical sensitivity of the 3M rapid detection influenza A+B assay. J Clin Microbiol 2008; 46:3804 – 7.
105. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and inter- pretation of rapid influenza tests in children. Pediatrics 2007; 119: e6 – 11.
106. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical spec- imens. J Clin Virol 2007; 39:132 – 5.
107. Rashid H, Shafi S, Haworth E, et al. Value of rapid testing for influenza among Hajj pilgrims. Travel Med Infect Dis 2007; 5:310 – 3.
108. Uyeki TM, Prasad PP, Vukotich C, et al. Low rapid influenza diag- nostic test sensitivity. Clin Infect Dis (in press).
109. McGeer AJ. Diagnostic testing or empirical therapy for patients hos- pitalized with suspected influenza: what to do? Clin Infect Dis 2009; 48(Suppl 1):S14 – 9.
110. Landry ML, Cohen S, Ferguson D. Real-time PCR compared to Binax NOW and cytospin-immunofluorescence for detection of influenza in hospitalized patients. J Clin Virol 2008; 43:148 – 51.
111. Cruz AT, Cazacu AC, Greer JM, Demmler GJ. Rapid assays for the diagnosis of influenza A and B viruses in patients evaluated at a large tertiary care children’s hospital during two consecutive winter seasons. J Clin Virol 2008; 41:143 – 7.
112. Rahman M, Kieke BA, Vandermause MF, Mitchell PD, Greenlee RT, Belongia EA. Performance of Directigen flu A+B enzyme immuno- assay and direct fluorescent assay for detection of influenza infection during the 2004 – 2005 season. Diagn Microbiol Infect Dis 2007; 58:413 – 8.
113. Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis 2004; 38:760 – 2.
114. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double- blind study of the safety, transmissibility and phenotypic and geno- typic stability of cold-adapted influenza virus vaccine, SLH. Pediatr Infect Dis J 2006; 25:590 – 5.
115. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175 – 81.
116. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resis- tance among influenza A viruses isolated early during the 2005 – 2006 influenza season in the United States. JAMA 2006; 295:891 – 4.
117. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to ada- mantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249 – 57.
118. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 2008; 56:51 – 7.
119. Sato M, Saito R, Sato I, et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, CZH, Japan. Tohoku J Exp Med 2008; 214:113 – 20.
120. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global sur- veillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395 – 402.
121. Neuraminidase Inhibitor Susceptibility Network. Monitoring of neu- raminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003 – 2006 influenza seasons. Wkly Epidemiol Rec 2007; 82:149 – 50.
122. Centers for Disease Control and Prevention. CDC issues interim rec- ommendations for the use of influenza antiviral medications in the settingof oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008 – 09 influenza season. 2008. Available at:http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNump00279. Ac cessed 28 January 2009.
123.Hauge SH, Dudman SG, Borgen K, Lackenby A, Hungnes O. Osel- tamivir-resistant influenza viruses A (H1N1), Norway, 2007 – 08. Emerg Infect Dis 2009; 15:155 – 62.
124. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48(Suppl 1):S3 – 13.
125. Besselaar TG, Dhamari N, Buys A, et al. Widespread oseltamivir re- sistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008; 14:1809 – 10.
126. Centers for Disease Control and Prevention. Update: influenza ac- tivity—United States, September 30, 2007 – February 9, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:179 – 83.
127. Ciancio B, Fernandez de la Hoz K, Kreidl P, et al. Oseltamivir resis- tance in human seasonal influenza viruses (A/H1N1) in EU and EFTA countries: an update. Euro Surveill 2008; 13:8032.
128. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:8026.
129. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21:626 – 38.
130. Nicoll A, Ciancio B, Kramarz P. Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential im- plications. Euro Surveill 2008; 13:8025.
131. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284 – 92.
132. Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005; 24:575 – 6.
133. Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int 2005; 47:484.
134. Shalabi M, Abughali N, Abzug M, et al., for the NIAID Collaborative Antiviral Study Group (CASG). Safety of osetamivir vs. adamantane or rmiantadine in children under 1 year of age. In: Program and abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America (San Diego). Alexandria, VA: Infectious Diseases Society of America, 2007.
135. Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother 1985; 27:309 – 13.
136. Knight V, McClung HW, Wilson SZ, et al. Ribavirin small-particle aerosol treatment of influenza. Lancet 1981; 2:945 – 9.
137. McClung HW, Knight V, Gilbert BE, Wilson SZ, Quarles JM, Divine GW. Ribavirin aerosol treatment of influenza B virus infection. JAMA 1983; 249:2671-4.
138. Wilson SZ, Gilbert BE, Quarles JM, et al. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother 1984; 26:200 – 3.
139. Rodriguez WJ, Hall CB, Welliver R, et al. Efficacy and safety of aero- solized ribavirin in young children hospitalized with influenza: a dou- ble-blind, multicenter, placebo-controlled trial. J Pediatr 1994; 125:129 – 35.
140. Stein DS, Creticos CM, Jackson GG, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 1987; 31:1285 – 7.
141. Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infec- tion. Antivir Ther 1996; 1:51 – 6.
142. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Che- mother 2008; 52:3889 – 97.
143. Madren LK, Shipman C, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir Chem Chemother 1995; 6:109 – 13.
144. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006; 3:CD001265.
145. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667 – 72.
146. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21:761 – 8.
147. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501 – 8.
148. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367:303 – 13.
149. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44(Suppl B):23 – 9.
150. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161:212 – 7.
151. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999 – 2000. J Am Geriatr Soc 2002; 50:608 – 16.
152. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an ob- servational study. Clin Infect Dis 2007; 44:964 – 7.
153. Nichols WG. Combating infections in hematopoietic stem cell trans- plant recipients. Expert Rev Anti Infect Ther 2003; 1:57 – 73.
154. Nichols WG. Management of infectious complications in the hematopoietic stem cell transplant recipient. J Intensive Care Med 2003; 18:295 – 312.
155. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult pa- tients: results from a retrospective population-based study. Curr Med Res Opin 2007; 23:2961 – 70.
156. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of in- fluenza-related complications and hospitalizations in patients with diabetes. Clin Ther 2007; 29:2246 – 55.
157. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and pre- vention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.
158. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775 – 85.
159. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240 – 6.
160. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016 – 24.
161. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123 – 9.
162. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influen- zavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874 – 80.
163. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and out- comes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568 – 75.
164. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127 – 33.
165. Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005; 24:225 – 32.
166. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007; 23:523 – 31.
167. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000; 19:410 – 7.
168. Randomised trial of efficacy and safety of inhaled zanamivir in treat- ment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lan- cet 1998; 352:1877 – 81.
169. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treat- ment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40:42 – 8.
170. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 1999; 180:254 – 61.
171. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus in- fection in children. Clin Infect Dis 2008; 47:339 – 45.
172. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759 – 65.
173. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase in- hibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009 (Epub ahead of print).
174. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug- resistant influenza A/H3N2 viruses shed during 1 year by an im- munocompromised child. Clin Infect Dis 2006; 43:1555 – 61.
175. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760 – 4.
176. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435 – 42.
177. van der Vries E, van den Berg B, Schutten M. Fatal oseltamivir- resistant influenza virus infection. N Engl J Med 2008; 359:1074 – 6.
178. Roche. Oseltamivir (package insert). Nutley, NJ: Roche, 2008. Avail- able at: http://www.rocheusa.com/products/tamiflu/pi.pdf.
179. US Food and Drug Administration. FDA Pediatric Advisory Com- mittee meeting on adverse event reports, focusing on neuropsychiatric and behavioral events, for Tamiflu (oseltamivir) (FDA transcript).2007.
180. Schnirring L. Japanese study finds no behavioral effects from Tamiflu. 2008. Available at: http://www.cidrap.umn.edu/cidrap/content/influ- enza/panflu/news/jul1108tamiflu-br.html. Accessed 21 November 2008.
181. McGeer AJ, Lee W, Loeb M, et al. Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for devel- opmentally disabled adults. Infect Control Hosp Epidemiol 2004; 25:955 – 61.
182. GSK. Zanamivir (package insert). Philadelphia: GSK, 2008. Available at: http://us.gsk.com/products/assets/us_relenza.pdf.
183. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180:254 – 61.
184. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
185. Williamson JC, Pegram PS. Respiratory distress associated with zan- amivir. N Engl J Med 2000; 342:661 – 2.
186. Murphy KR, Elvindson A, Pauksens K, Stein WJ. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Investig 2000; 20:337 – 49.
187. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27 – 72.
188. Hayden FG, Pavia AT. Antiviral management of seasonal and pan- demic influenza. J Infect Dis 2006; 194(Suppl 2):S119 – 26.
189. Oseltamvir, amantadine (review) and zanamivir for the prophylaxis of influenza. London: National Institute for Health and Clinical Ex- cellence, 2008.
190. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W.
Emergence and apparent transmission of rimantadine-resistant influ- enza A virus in families. N Engl J Med 1989; 321:1696 – 702.
191. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343:1282 – 9.
192. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir pro- phylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582 – 8.
193. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440 – 9.
194. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized con- trolled trial. JAMA 2001; 285:748 – 54.
195. Rubin MS, Nivin B, Ackelsberg J. Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza A in adult long-term care facilities. Clin Infect Dis 2008; 47:47 – 52
196. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025 – 31.
197. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004; 39:459 – 64.
198. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long- term care population. J Am Med Dir Assoc 2005; 6:359 – 66.
199. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell trans- plantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85:278 – 87.
200. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a ret- rospective case-control study. Clin Infect Dis 2007; 45:187 – 93.
201. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123:518 – 27.
202. Nichol KL, Margolis KL, Wouremna J, von Sternberg T. Effectiveness of influenza vaccine in the elderly. Gerontology 1996; 42:274 – 9.
203. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:430 – 3.
204. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1 – infected patients. J Acquir Immune Defic Syndr 2005; 39:167 – 73.
205. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected indi- viduals: a consecutive 3-year study. Vaccine 2000; 18:3040 – 9.
206. Smith PW, Bennett G, Bradley S, et al. SHEA/APIC guideline: infec- tion prevention and control in the long-term care facility, July 2008. Infect Control Hosp Epidemiol 2008; 29:785 – 814.
207. Bradley SF. Prevention of influenza in long-term-care facilities. Long- Term-Care Committee of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1999; 20:629 – 37.
208. Sneller VP, Izurieta H, Bridges CB, et al. Prevention and control of vaccine-preventable diseases in long-term care facilities. J Am Med Dir Assoc 2000:S1-37.
209. Drinka PJ, Krause P, Nest L, Goodman BM, Gravenstein S. Risk of acquiring influenza A in a nursing home from a culture-positive roommate. Infect Control Hosp Epidemiol 2003; 24:872 – 4.
210. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: im- plications for control in health care settings. Clin Infect Dis 2003; 37:1094 – 101.
211. Gomolin IH, Leib HB, Arden NH, Sherman FT. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and man- agement. J Am Geriatr Soc 1995; 43:71 – 4.
212. Siegel J, Rhinehart E, Jackson M, Chiarello L; the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. 2007. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ guidelines/isolation2007pdf. Accessed 4 March 2009.
213. Zadeh MM, Buxton Bridges C, Thompson WW, Arden NH, Fukuda K. Influenza outbreak detection and control measures in nursing homes in the United States. J Am Geriatr Soc 2000; 48:1310 – 5.
214. Bridges CB, Harper S. The full-court press for influenza prevention in elderly persons. Clin Infect Dis 2004; 39:465 – 7.
215. Drinka PJ, Gravenstein S, Krause P, et al. Non-influenza respiratory viruses may overlap and obscure influenza activity. J Am Geriatr Soc 1999; 47:1087 – 93.
216. Ellis SE, Coffey CS, Mitchel EF Jr, Dittus RS, Griffin MR. Influenza- and respiratory syncytial virus – associated morbidity and mortality in the nursing home population. J Am Geriatr Soc 2003; 51:761 – 7.
217. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21:700 – 4.
218. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep 2001; 27:37 – 40.
219. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998; 16:1771 – 4.
220. van der Sande MA, Ruijs WL, Meijer A, Cools HJ, van der Plas SM. Use of oseltamivir in Dutch nursing homes during the 2004 – 2005 influenza season. Vaccine 2006; 24:6664 – 9.
221. Cohen NJ, Morita JY, Plate DK, et al. Control of an outbreak due to an adamantane-resistant strain of influenza A (H3N2) in a chronic care facility. Infection 2008; 36:458 – 62.
222. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224 – 8.
223. Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for in- fluenza. J Infect Dis 2007; 196:181 – 90.
224. Whitley RJ, Monto AS. Prevention and treatment of influenza in high- risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006; 194(Suppl 2):S133 – 8.
225. Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. J Am Geriatr Soc 2005; 53:444 – 51.
226. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vac- cination of health-care workers on mortality of elderly people in long- term care: a randomised controlled trial. Lancet 2000; 355:93 – 7.
227. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175:1 – 6.
228. Pachucki CT, Pappas SA, Fuller GF, Krause SL, Lentino JR, Schaaff DM. Influenza A among hospital personnel and patients: implications for recognition, prevention, and control. Arch Intern Med 1989; 149:77 – 80.
229. Drinka PJ, Gravenstein S, Schilling M, Krause P, Miller BA, Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols. Arch Intern Med 1998;158:2155 – 9.